Showing results (341-350 of 601) with videos related to
Sort By:
Pageof 61
Neurological Research and Practice|April 1, 2021
Consequences of COVID-19 pandemic lockdown on emergency and stroke care in a German tertiary stroke centerRobin Jansen, John-Ih Lee, Bernd Turowski, et al.Journal of the Peripheral Nervous System : JPNS|April 29, 2023
An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathyLuis Querol, Richard A Lewis, Hans-Peter Hartung, et al.Brain : a Journal of Neurology|March 26, 2002
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10Bernd C Kieseier, Marie Tani, Don Mahad, et al.The Lancet. Neurology|February 8, 2014
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThomas P Leist, Giancarlo Comi, Bruce A C Cree, et al.Journal of Neurology|January 13, 2005
European validation of a standardized clinical description of multiple sclerosisMaria Pia Amato, Jerome Grimaud, Iuliana Achiti, et al.Trends in Molecular Medicine|December 22, 2019
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging ImmunotherapiesAmit Bar-Or, Michael P Pender, Rajiv Khanna, et al.Biomedicines|December 24, 2021
Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-AnalysisMoritz Förster, Christopher Nelke, Saskia Räuber, et al.Acta Neuropathologica|July 5, 2014
CD19 as a molecular target in CNS autoimmunityOlaf Stüve, Clemens Warnke, Krystin Deason, et al.Brain Communications|April 28, 2022
Tissue donations for multiple sclerosis research: current state and suggestions for improvementPatrick Vanderdonckt, Francesca Aloisi, Giancarlo Comi, et al.Brain Communications|November 10, 2021
Relapse-independent multiple sclerosis progression under natalizumabJonas Graf, Verena I Leussink, Giulia Soncin, et al.Pageof 61